Drugs Made In America Acquisition II Corp. carries no debt; cash flow comfortably covers obligations.

Drugs Made In America Acquisition II Corp.'s free cash flow has decreased 424.05% from $-194.30K last year to $-1.02M, signaling decreasing performance

Drugs Made In America Acquisition II Corp.'s debt to equity ratio is 0.00, which means that the company's assets are healthy financed, signaling financial stability.

Drugs Made In America Acquisition II Corp.'s debt has increased relative to shareholder equity from -2.14 last year to 0.00 today, signaling weakened financials

Drugs Made In America Acquisition II Corp. has a net cash position, so leverage is healthy.

Drugs Made In America Acquisition II Corp. earns at least as much interest as it pays. Interest obligations are fully covered.

Drugs Made In America Acquisition II Corp. has insufficient data to evaluate this check.

Drugs Made In America Acquisition II Corp.'s short-term liabilities of $300.86K exceed its short-term assets of $26.04K, signaling financial risk

Drugs Made In America Acquisition II Corp.'s return on assets of 2.53% is lower than the 5.00% threshold, indicating inefficient asset utilization

Drugs Made In America Acquisition II Corp.'s return on equity of 2.66%, is lower than 15.00%, indicating bad performance

Drugs Made In America Acquisition II Corp.'s operating cash flow is lower than its net income, indicating that earnings may not be fully backed by cash generation

Drugs Made In America Acquisition II Corp. has insufficient public price history to evaluate earnings stability.

Drugs Made In America Acquisition II Corp. has negative free cash flow, indicating the company is burning cash rather than generating it

Drugs Made In America Acquisition II Corp. has negative free cash flow, indicating cash burn

Drugs Made In America Acquisition II Corp.'s yearly earnings has increased 2.86K% since last year from $-151.72K to $4.19M, signaling increasing performance

Drugs Made In America Acquisition II Corp. has insufficient data to evaluate this check.

ROIC -0.28% (Source: FMP key-metrics). Below the 5% partial-credit threshold. Score: 0 of 2. The 5% and 10% cutoffs anchor to typical US weighted-average cost of capital. Below 5% indicates the company is not generating returns above its likely cost of capital under this definition of invested capital. Invested capital here includes equity, non-current liabilities (pension obligations, deferred taxes, lease obligations), and short-term debt. Cash is not subtracted. Companies with substantial float, lease portfolios, or cash holdings will score lower under this definition than under narrower operating-capital definitions. See methodology.

Drugs Made In America Acquisition II Corp. has insufficient revenue history to calculate 3-year revenue CAGR.

Drugs Made In America Acquisition II Corp. has insufficient public price history to evaluate revenue consistency.

Drugs Made In America Acquisition II Corp. has insufficient public price history to evaluate ROE consistency.

Drugs Made In America Acquisition II Corp. has insufficient data to evaluate this check.

Drugs Made In America Acquisition II Corp. has an earnings yield of 325.91%, which is above the 4.00% threshold, indicating the stock offers reasonable value relative to its earnings

Drugs Made In America Acquisition II Corp. is overvalued relative to its fair value price of 0.00 based on Base EBITDA Valuation model

Drugs Made In America Acquisition II Corp. has negative or missing EBITDA, making EV/EBITDA ratio unreliable

Drugs Made In America Acquisition II Corp. has insufficient data to evaluate this check.

Drugs Made In America Acquisition II Corp. has insufficient diluted EPS history to calculate the PEG ratio.

Drugs Made In America Acquisition II Corp. has a price-to-book ratio of 0.01x, which is below the 5.00x threshold, indicating reasonable valuation relative to its book value

Drugs Made In America Acquisition II Corp. has a price-to-sales ratio of 999.00x, which exceeds the 8.00x threshold, indicating the stock may be overvalued relative to its revenue